390 results
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
8 Jan 24
Regulation FD Disclosure
10:29am
growth potential 1. Subject to satisfaction of customary closing conditions; anticipated closing of RayzeBio in 1H 2024
11 major brands across 4 TAs + 12 … -adjusted consensus annual sales; Only logos for major brands are shown 1. Subject to satisfaction of customary closing conditions; anticipated closing
SC TO-T
EX-99
MYOK
MyoKardia, Inc.
19 Oct 20
Third party tender offer statement
6:03am
”), subject to the satisfaction or waiver of the other conditions set forth in the Merger Agreement and in any event no later than one business day … following the satisfaction or waiver of such conditions, Purchaser will merge with and into MyoKardia (the “Merger”), with MyoKardia continuing
8-K
EX-99.2
BMY
Bristol-Myers Squibb Co.
2 Feb 24
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
7:46am
. Mirati Therapeutics acquisition closed January 2024; 2. Subject to satisfaction of customary closing conditions; Karuna Therapeutics & RayzeBio in 1H … potential 1. Subject to satisfaction of customary closing conditions; anticipated closing of RayzeBio in 1H 2024
Q4 2023 Results Not for Product
SC TO-T
EX-99
MYOK
MyoKardia, Inc.
19 Oct 20
Third party tender offer statement
6:03am
FOR PAYMENT (THE “OFFER ACCEPTANCE TIME”), SUBJECT TO THE SATISFACTION OR WAIVER OF THE OTHER CONDITIONS SET FORTH IN THE MERGER AGREEMENT AND IN ANY … EVENT NO LATER THAN ONE BUSINESS DAY FOLLOWING THE SATISFACTION OR WAIVER OF SUCH CONDITIONS, PURCHASER WILL BE MERGED WITH AND INTO MYOKARDIA
8-K
BMY
Bristol-Myers Squibb Co.
11 Aug 05
Entry into a Material Definitive Agreement
12:00am
in the Agreement, BNP Paribas and The Royal Bank of Scotland plc, as arrangers, and The Royal Bank of Scotland plc, as agent.
Upon satisfaction of various initial … on August 5, 2007. Borrowings under the facilities are also subject to the satisfaction at the time of customary conditions to utilization.
Loans under
8-K
wp5m7qi8axlmhqd8t
19 Dec 13
Entry into a Material Definitive Agreement
12:00am
S-3
EX-5
cmwvr ieqw9
20 Jul 95
Shelf registration
12:00am
SC TO-T
EX-99
pq5wxbl3etgfy78wzpe8
19 Oct 20
Third party tender offer statement
6:03am
SC TO-T
EX-99
rkmr7oj24n
25 Jan 24
Third party tender offer statement
8:13am
SC TO-T
EX-99
nmqf5e977nomrk4cgg
19 Oct 20
Third party tender offer statement
6:03am
8-K
EX-4.1
640p6wwa2z gzgszi5d
12 Nov 09
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
12:00am
S-4/A
EX-5.1
alp x6p47ydbyi0u1
19 Sep 96
Registration of securities issued in business combination transactions (amended)
12:00am
SC TO-T
EX-99
5d54lf5 vr1
17 Jun 22
Third party tender offer statement
4:42pm
SC TO-T
EX-99
l8vjhr6rk 3ylxgz
25 Jan 24
Third party tender offer statement
8:13am
8-K
EX-99.1
ll7kfhmfz84s aw4j
6 Feb 14
Bristol-Myers Squibb Completes Previously Announced Sale of Global Diabetes Business to AstraZeneca
12:00am
8-K
EX-99.2
kj15 31vfo7
26 Oct 23
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
7:44am
SC TO-T
EX-99
ty1z9cb
17 Jun 22
Third party tender offer statement
4:42pm
8-K
zkq1bq97qihk634cgu
17 Mar 06
Changes in Registrant.s Certifying Accountant
12:00am